Researchers unveiled an improved genome-engineering technique, “prime assembly,” designed to enable efficient insertion of large DNA fragments into genomes. The approach targets a longstanding bottleneck in gene therapy and genetic manipulation: integrating sequences larger than 400 base pairs. The reported advance aims to expand editing capability beyond small edits, potentially supporting correction strategies that require full gene replacement segments rather than only mutation-level fixes. As the method moves from proof-of-concept toward translational feasibility, key industry questions will likely center on editing efficiency, error profiles, delivery constraints, and scalability for therapeutic-grade manufacturing. For gene-therapy platforms, the larger-fragment angle is a direct attempt to widen the addressable mutation classes and therapeutic use cases.